Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for bladder overactivity after prostatectomy
ChiCTR2000036134Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of mirabegron in benign prostatic hyperplasia (BPH) and overactive bladder (OAB) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Overactive bladder symptom score (OABSS). Started Sep 2020; status: recruiting.
02
Drugs
mirabegron
03
Conditions
benign prostatic hyperplasia (BPH)overactive bladder (OAB)
Beyond the preview
Go deeper on ChiCTR2000036134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036134.